Ascendis Pharma AS (ASND) — the earnings record
Computed on 2026-09-18 from the vendor's per-print history with the Print Record's method — no desk-written read yet. An investment research diary, not advice.
The record at a glance
Reactions across the covered prints span -11.5% to +23.8% — the beat column and the reaction column frequently disagree, which is the whole reason the record scores them separately. The street carries est EPS $1.08 · est revenue ~$0.48B into the next print.
Print by print
| Date | EPS | Revenue | |
|---|---|---|---|
| Aug 26 | 2026-08-13 | ✓ beat | ✓ beat |
| May 26 | 2026-05-07 | ✓ beat | ✗ miss |
| Feb 26 | 2026-02-11 | ✗ miss | ✓ beat |
| Nov 25 | 2025-11-12 | ✗ miss | ✗ miss |
| Aug 25 | 2025-08-07 | ✓ beat | ✗ miss |
| May 25 | 2025-05-01 | ✗ miss | ✗ miss |
| Feb 25 | 2025-02-12 | ✓ beat | ✓ beat |
| Nov 24 | 2024-11-14 | ✓ beat | ✗ miss |
| Sep 24 | 2024-09-03 | ✗ miss | ✓ beat |
| May 24 | 2024-05-02 | ✗ miss | ✓ beat |
Report-day close to the close three sessions later on adjusted closes, ±3% bands — the same method as every hand-written card; the Print Record method explains the bands. No reaction chart, metric line or behavior read exists for ASND yet.
FAQ · from the current data · as of 2026-09-18
Quick answers
How often does Ascendis Pharma AS beat earnings estimates?
Across the last 10 covered prints (as of the 2026-09-18 card), Ascendis Pharma AS beat EPS estimates 5 of 10 times and revenue estimates 5 of 10 times, with 2 double beats.
How does ASND stock react to earnings?
Measured close-of-print-day to the close three sessions later: 2 of the last 10 prints resolved up (beyond +3%), 5 flat, 3 down — reactions spanning -11.5% to +23.8%. Beat-or-miss and reaction are scored separately because they frequently disagree.
What was ASND's biggest earnings reaction?
+23.8% over the three sessions after the Feb 25 print (2025-02-12).
When does Ascendis Pharma AS report earnings next?
2026-11-11 (2026-11-11 · est EPS $1.08 · est revenue ~$0.48B). This record is computed from the vendor's per-print history with the Print Record's method; a desk-written card for ASND does not exist yet. An investment research diary, not advice.
Related in the Closelook universe
then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- BION.SW BB Biotech AGindustry
- ARGX.BR Argen-Xindustry
- ARGX argenx NV ADRindustry
- ONC BeiGene, Ltd.industry
- REGN Regeneron Pharmaceuticals Incindustry
- UCB.BR UCB SAindustry
- MRNA Moderna Incindustry
- TWST Twist Bioscience Corpindustry
- ONT.L Oxford Nanopore Technologies Ltdindustry
- SMMT Summit Therapeutics PLCindustry
- HALO Halozyme Therapeutics Incindustry
- TLX.AU TELIX Pharmaceuticals Ltdindustry
- SRPT Sarepta Therapeutics Incindustry
- GMAB Genmab ASindustry
- IBRX Immunitybio Incindustry
- CRSP Crispr Therapeutics AGindustry
- EXEL Exelixis Incindustry
- TGTX TG Therapeutics Incindustry
- MRVI Maravai Lifesciences Holdings Incindustry
- INCY Incyte Corporationindustry